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Abstract  
Recent breakthroughs in diagnostics, genotyping and so forth, has created opportunities to 
satisfy the individual therapeutic needs of each patient, i.e. treatment can be tailored according 
to the patient’s biological attributes as well as according to behavioural and environmental 
factors. Medicines, when tailored to the individual needs are often referred to as personalized 
medicines. So far, pharmaceutical production platforms are dominated by mass production in a 
batch manner with limited possibilities to fully satisfy the emerging customization needs of 
pharmaceutical products. To face the challenge of customization in an economically feasible 
manner, re-engineering of the product and production concept is inevitable. The aim of the 
present work is to introduce a novel approach to customize treatments by structural 
parameterization of the medicinal product concept. The primary adaption is here evaluated for 
solid oral dosage forms (SODFs), e.g. tablets. The tablet concept is re-designed to embrace a 
modular architecture. A platform approach, more specifically the Configurable Component 
(CC) method (Claesson, 2006), is used for efficient configuration of product families. To 
support the design work, computer-aided design tools are used. The Configurable Component 
modeller (CCM) (Claesson, op. cit.) is used for the function-means tree modelling of the tablet 
concept and from this product variants are automatically generated. The properties of the 
generated product families are then evaluated with regards to following criteria; product variety 
and manufacturing complexity to identify critical trade-offs. 
 
Keywords: Product Design, Digital Design, Product Platforms, Platform-based Design, 
Personalized Medicines, Mass Customization 
1 Introduction 
In recent years breakthroughs have been made in diagnostics, genotyping and so forth, which 
has created opportunities to satisfy the individual therapeutic needs of each patient (Crommelin 
et al., 2011). This means, that a patient can be offered an optimal treatment according to the 
patient’s biological attributes such as for example genetics, age, and weight, according to 
behavioral factors such as for example administration difficulties, as well as environmental 
factors such as UV exposure, food and alcohol habits, as well as severity of dehydration. The 
factors mentioned above can be compared to functional requirements and constraints and can 
be connected to design parameters (Tjalve, 1979; Suh, 1990) such as the active pharmaceutical 
ingredient (API), the dose of the API, and the composition of the dosage form. Medicines, when 
tailored to the individual needs and designed according to these design parameters are often 
referred to as personalized medicines (Govender et al., 2017). 
  
So far, pharmaceutical production platforms are dominated by mass production in a batch 
manner due to a highly regulated production environment (Plumb, 2005; Lee et al., 2015). A 
prevailing batch production paradigm is limiting the possibilities to fully satisfy the emerging 
customization needs of pharmaceutical products. 
 
Approaches to customization of medicines are emerging in literature and mainly presented from 
two separate ends. The first end focuses on empirical attempts to customization of the product 
concept and the second end is focusing on an efficient production and a flexible handling of the 
increasing amount of product variants in the supply chain, which is a consequence from 
customization.  
 
A direct consequence of moving from mass production to mass customization is not only the 
decreasing production volumes per product variant but also the increasing requirement on the 
flexibility of production, stemming from the increasing number of product variants. To 
approach these challenges continuous production processes for primary active ingredient 
processing as well as secondary formulation processing is widely researched (Lee et al., 2015). 
Additionally, reconfiguration of the supply chain of medicine production by adopting 
continuous processing technologies and integrating these with downstream processes such as 
product packing and distribution as an ambition to support management of increasing number 
of product variants has been evaluated (Srai et al., 2015).  
 
However, we have not been able to find any reports regarding the integration of the product 
concept for customization with the production concept in the literature. To fulfil this gap, 
inspiration from the manufacturing industry could be taken. Thus, the present work suggests a 
novel approach to customize treatments, specifically solid oral dosage forms (SODF) of 
treatments, e.g. tablets, by adapting methodologies from manufacturing industry and applying 
these to enable mass customization of medicines. More specifically the Configurable 
Component (CC) method (Claesson, 2006), which is an expanded function-means tree 
modelling approach, has been used as an approach to establish a SODF product platform and 
to support efficient configuration of product families. A product family, in this study, is aligned 
with the definition by (Meyer & Lehnerd, 1997) and characterized by sets of product variants 
that share the same components as configurational means. Empirical attempts to customization 
of medicines have been reported in the literature but we have not found any reports regarding 
structural parameterization of the product concept. The focus of this study will thus be aimed 
at the product concept design but evaluations of the design implication on the manufacturing 
complexity will also be performed. However, the production concept of these customized 
medicines is out of the scope of this study. A discussion is conducted regarding the product 
design implications on the level of customization as well as the manufacturing complexity and, 
the sufficiency of the model to evaluate manufacturing complexity is assessed. 
 
Manufacturing industries, especially industries for discrete part production, such as for example 
the automotive industry, have realized the value of mass customization, i.e. producing streams 
of product variants, product families, to fulfill the needs of stratified customer groups, 
increasing the attractiveness of products, and thus, improve sales (Ho & Tang, 1998; Wortmann 
et al., 1997). Therefore, manufacturing industries have worked towards adopting methodologies 
to enable mass customization in an economically feasible manner. Product platforms are an 
example of such methodology and can be described as a technology, founded in a common 
structure, i.e. product architecture, and sets of subsystems and interfaces, that supports an 
efficient development and configuration of sets of product variants, called product families 
(Meyer & Lehnerd, 1997). According to Ulrich and Eppinger (2012), a product architecture is 
a basis for enabling configurations of product variants. Two approaches to this were presented 
by Du et al. (2012), a modular product architecture approach or a scalar architecture approach.  
 
Levandowski et al. (2014) developed an integrated product and manufacturing platform model 
and applied for a case study in the aerospace industry, see figure 1 for an overview of the model. 
In this platform approach, the modelling is performed by the CC method which is an approach 
to function-means tree modelling and a tool for a joint modular and scalar product architecture 
approach to enable product variety (Claesson, 2006). The CC method provides a system 
structure, product architecture, that consists of several configurable subsystems, configurable 
components, operating independently but providing functions to the overall performance of the 
system. These independent subsystems provide the system with a modular structure. The 
modelling of functions and the design solutions of the functions of each configurable 
component, subsystem, is realized through function-means tree modelling. This allows for 
design bandwidths of each function and its design solution, and hence a scalable design of the 
subsystems is achieved (Claesson, op. cit.).  
 
The remainder of the paper is organized as follows; section 2 describes the method used in this 
study, the modelling approach, as well as the experimental set-up and clarifies assumptions 
made. Section 3 presents and discusses the results of the modelling as well as from the 
experimental work and section 4 concludes the work and discusses opportunities for future 
work. 
Figure 1. An overview of the integrated product and manufacturing platform (Levandowski et al. 2014). 
2 Method 
This section provides a short description of the system modelling approach, the experimental 
work carried out, and assumptions made during modelling.  
2.1 System model and experimental set-up 
To conceptually structure a solid oral dosage form (SODF), more specifically in this study a 
tablet, into its functions, the CC method is used. In this study, the tablet is embracing a modular 
architecture and thus, the subsystems of the product architecture are physically realized by 
standardized modules. These modules are the building blocks of the tablet and embed one or a 
few functions of the tablet. More specifically, this study focuses on the functions treat disease 
and provide a suitable size of the SODF and thus, the standardized modules used for product 
configurations are modules containing an active pharmaceutical ingredient (API module) and 
modules for filling purposes (filling module). A system configuration, a product variant, is 
realized as an assembled entity.  
 
To identify opportunities with a modularized tablet concept, system model evaluations needs 
to be performed and for this purpose, the cases presented in table 1 are simulated. The different 
cases, use different sizes and combinations of standardized API modules as building blocks to 
configure a product variant.  
 
Module sizes that the different cases use for product configuration are marked x in table 1. For 
example, case A uses API module of a single size, 1, and case D uses a combination of two 
sizes of API modules, sizes 1 and 5, and so forth for configuring product variants. The API 
module sizes are given in mass units since this is the commonly used unit for dosages of 
medications, usually given in mg, but to keep it general the expression mass units is used.  
 
The drug loading of the API modules is set to 80% (80% of the module consists of the API and 
the remaining consists of another material, for example, material for binding purposes) and the 
proportionality constant for converting mass units into volume units is set to 1 for the API 
modules. The order of magnitude of these modules are in mm3, but to keep it general the 
expression volume units is used. The API modules are embracing a cubic shape. Additionally, 
each case has access to filling modules of one standardized size, 1 mass unit, for system filling 
purposes. The proportionality constant for converting mass units into volume units is set to 1. 
The filling modules are embracing a cubic shape. 
 
Table 1. Cases for system model simulations. Module sizes that the different cases use for product 
configuration are denoted x in the table. 
 
 API modules Filling modules 
1 mass unit 5 mass units 10 mass units 1 mass unit 
Cases A x   x 
B  x  x 
C   x x 
D x x  x 
E x  x x 
F  x x x 
G x x x x 
2.1.1 System size and shape 
The minimum size of the system is set as 4 volume units embracing a cuboid shape and 
dimensions of 2 × 2 × 1. This follows results from a study performed on children’s, aged 0.5-
5 years, preferred medication, concluding that mini-tablets of a cylindrical geometry with a 
diameter of 2 mm was the preferred choice (the height not stated) (Klingmann et al., 2013). 
 
The Food and Drug Administration (FDA) (2015) provided recommendations regarding largest 
tablet and capsule sizes to ensure convenient administration. These provided measurements 
such as the largest dimension of a tablet should not exceed 22 mm and the capsule size should 
not exceed the standardized capsule size 00. A capsule size 00 has slightly different size 
properties depending on the manufacturer and in this study, the size properties are chosen 
according to capsules produced by Medisca (n.d.). The overall closed length of a 00 size capsule 
is 23.3 ± 0.3 mm, dimension 𝑙𝑐 in figure 2, the external diameter of the body part is given as 
8.18 ± 0.06 mm, dimension d in figure 2. The cap part has a slightly larger diameter, 8.53 ± 
0.06 mm, but as a measurement, the body diameter is used. 
  
To comply with the FDA recommendations regarding tablet and capsule sizes, but 
simultaneously simplify the calculations, it is assumed that a capsule of size 00 is enclosing a 
rectangular cuboid where the smallest face embraces a square geometry. The diagonal of the 
smallest face, denoted 𝑑 in figure 2, is equal to the largest diameter of the capsule, stated as 
8.18 mm above. The capsule is assumed to embrace the form of a cylinder with full half spheres 
attached at the respective end and thus, the length of the rectangular cuboid, denoted 𝑙𝑟 in figure 
2, has the same length as the cylindrical part of the capsule. The volume of the cuboid is then 
506 volume units and this value is used in the simulations as the maximum system volume. 
Additionally, it is assumed that if the total volume of the modules in the system is less or equal 
to the maximum volume depicted here, they still assemble to a conveniently sized tablet. The 
order of assembly of the modules and thus, the resulting geometry of the assembly is out of the 
scope of this study. 
2.2 System simulation and data analysis 
The system response is evaluated for two scenarios: 
• 5 dose levels; [20:20:100] 
• 100 dose levels; [1:1:100]  
The smallest dose, the step length in between the dose levels and the largest dose are stated 
inside the brackets. 
 
A combinatorial problem is solved to calculate the number of product variants, system 
configurations, that each case presented in table 1 can generate for each dose level. All the 
product variants for each case represents a product family. The combinatorial problem is solved 
Figure 2. A capsule enclosing a cuboid seen from two perspectives and including the dimensions for 
calculations of the maximum volume of the system. 
in the CCM software (Claesson, 2006), which compiles a list of all product configurations. This 
list is then exported to MATLAB to filter the data as well as to calculate the number of product 
variants. 
 
The manufacturing complexity, as an indication of the assembly cost, of a product variant is 
evaluated by applying the complexity factor, introduced by Pugh (1990). According to Pugh 
the complexity factor, 𝐶𝑓, can be defined as follows if the number of functions are equal for 
each product variant;  
𝐶𝑓 ∝ √𝑁𝑝𝑁𝑡𝑁𝑖
3        (1) 
 
Where 𝑁𝑝 is the number of parts, 𝑁𝑡 is the number of types of parts and 𝑁𝑖 is the number of 
interconnections and interfaces in between the parts in an assembly.  
 
To calculate the number of interfaces, 𝑁𝑖, in between each module in a product configuration, 
the order of assembly needs to be known. As assembling of the modules is outside the scope of 
this study, the following is assumed; each face of a module is interconnecting to exactly one 
other module (as if each module would be of the same size). The form of the total assembly is 
maximized as a cube and the leftover modules are assembled as additional rows in one 
dimension. The calculations are performed in MATLAB. Since each case can generate a family 
of product variants solely at one dose level, to simplify analysis the mean number of the 
complexity factor on each dose level is calculated for each product family. 
3 Results and discussion 
This section presents the resulting system model of the tablet, as well as, the results from the 
system simulations and trade-off curves of compiled results. Discussions of the results are 
provided. 
3.1 Adaption of function-means tree modelling to medicinal product design 
Figure 3 presents a suggested architecture of a solid oral dosage form (SODF) structured 
conceptually into its functions and encapsulated as independent subsystems with the aid of the 
CC method. This architecture is describing a tablet containing an active pharmaceutical 
ingredient (API) and filling material. 
 
Each autonomous CC object in figure 3 embeds an enhanced function-means tree that describes 
the design rationale (DR) of that subsystem and thus, consists of the functional requirements 
(FR), design solutions (DS) and constraints (C) of the subsystems. In the architecture of a 
SODF, the primary function is to provide treatment, hence the FR of the CC object is Provide 
treatment. This FR is realized through the DS tablet. The tablet is constrained with regards to 
size, a minimum volume of 4 volume units and a maximum volume of 506 volume units. Even 
though, the FR provide treatment is realized by the DS tablet it is not restricted to one DS but 
could as well be realized by several DSs, such as for example capsule filled with pellets. But, 
as the first attempt to functional modelling of a tablet the focus is rather on evaluating if 
functional modelling of a tablet can be made using the CC method, and thus, only a few 
functions of a tablet has been included in the model. 
 
 
 
The DS tablet is structured into sub-functional requirements (sub-FRs) such as Treat disease 
and Provide suitable size. These sub-FRs are realized by the DS API modules and DS Filling 
modules respectively. Each sub-FR interacts with one another to form a system, the tablet, and 
thus this is encapsulated as a CC object. Likewise, the DSs to the FRs of the CC object Tablet  
are realized through independent subsystems and thus, are encapsulated into autonomous CC 
objects. 
 
The design solutions API modules and Filling modules are further structured into sub-FRs, such 
as Treat disease, Bind material, Modify release, Define size, Define shape and Provide material 
for the DS API modules and Filling material, Define size and Define shape for the DS Filling 
modules. These sub-FRs are realized by respective design solution and thus, composes 
autonomous CC objects. Note, that the FR Define size of the CC object API modules is realized 
through several design solutions and thus, provides a set of alternative solutions to that function, 
hence, platform approach.  
 
The CC objects API modules and Filling modules are modelled as one CC object respectively 
but the physical realization of the CC object consists of several modules. For example, a product 
variant is not configured from solely one API module providing a dose of 20 units, but rather 
20 modules providing a dose of 1 unit each and as a system constitutes the whole dose of 20 
units. This is possible to model due to the scalability properties of the CC method and thus, a 
modelling decision was made to scale the number of modules used to generate product variants 
of the CC object, simply, to increase the flexibility of configuring product variants and thus, 
increase the opportunities of product customization. Not only, by varying the number of API 
modules, can systems of different doses be configured, but also, by varying the number of filling 
modules, variety regarding size and shape of the systems can be facilitated, and thus, this could 
aid treatment of children and elderly as it has been reported that these groups pose 
administration difficulties (Breitkreutz & Boos, 2007). This, however, differs from the 
modelling approach in the manufacturing industries where the scalability property is generally 
used to, for example, tamper with the size of one object and not to tamper with the number of 
standardized objects. 
 
Modularizing the tablet concept is not restricted to the increased level of customization of one 
treatment solely but, provides an opportunity for combination therapeutics. Combining several 
Figure 3. The architecture of SODF modelled by using the Configurable Component method. 
API into one tablet could especially aid an ageing population who generally are under several 
treatments. At the extreme, each module in the system, the tablet, could be a unique active 
pharmaceutical ingredient (API). However, restrictions arise from the resulting sizes of the 
tablets to still prevail a convenient administration. A large dose indicates increasing number of 
modules and thus, the size of the system can rapidly increase. Material properties is another 
restriction to freely modularize, assemble and combine. Material suitability is essential, 
especially highly potent active pharmaceutical ingredients might restrain opportunities. 
3.2 Design and the implications for system response 
Figures 4 and 5 present results from system simulations, of system configurations, consisting 
of one API, for product families of five and 100 dose levels. Note that the simulations for 100 
dose levels, do not present cases B, C and F. That is since the sizes of the modules are 
inconvenient and thus, cannot provide a product variant of each dose level simulated. 
 
Figure 4 presents the lowest resulting assembly cost, indicated by the complexity factor, of each 
case at each dose level. For 5 dose levels a minimized assembly cost is provided by product 
variants of product families for cases C, E, F and G and for 100 dose levels a minimized 
assembly cost is provided by a product variant of the product family for case G. A minimized 
assembly cost requires increased sizes of standardized modules, but on the contrary, an 
increased module size might not be able to provide product variants for each dose desired. A 
product family consisting of several standardized modules of different sizes can result in low 
complexity factor by configuring a product variant from the module combinations giving the 
lowest complexity factor but simultaneously generate product variants for each dose level 
desired.  
 
The lowest assembly cost can give an indication of the best system design only if the dose of 
the system is considered and thus, the product variant of a product family minimizing the 
assembly cost is considered as the suitable system design. However, a product family can 
provide several product variants, equal with regards to the system dose, but unique regarding 
the combinations of modules used as building blocks for product variant configuration. Thus, 
these product variants differ from each other with regards to size and shape, which can be varied 
with the aid of filling materials as well as with the aid of different module types, which in this 
study are differing in size. Considering that the size and the shape of a tablet are proven to have 
an impact on the release of the API in the body, the order of assembly of the modules is 
important (Goyanes, 2015; Siepmann & Siepmann, 2012). This facilitates opportunities to 
Figure 4. The lowest assembly cost indicated by complexity factor of product variants for each dose level of 
each product family, at 5 and 100 dose levels. 
manipulate the release rate of a system solely by introducing different assembly sequences. 
Product families can construct several unique product variants at one dose level and thus, 
increase the level of customization. Even though assembling of the modules is out of the scope 
of this study and thus, the resulting shape of the assembled product variants will not be 
discussed in more detail, it is important to point out that the increasing number of product 
variants provides opportunities for customization in various ways and thus, solely choosing the 
complexity factor as an indicator for best design is not sufficient. 
 
Trade-offs between the number of product variants and the ratio of the number of product 
variants and the complexity factor for product families are presented in figure 5 to emphasize 
an increased customer value (associated with an increased level of customization) and thus, 
judged to provide a better foundation for design decision making. On the horizontal axis, the 
resulting product families are ordered in an increasing order with regards to the number of 
product variants. The number of product variants is plotted on the primary axis, to the left, and 
given as a sum of every product variant of each product family at all dose levels simulated, 
solely considering the unique combinations the modules can generate. The ratio of the number 
of product variants and the complexity factor is plotted on the secondary axis, to the right. The 
ratio, in this case, is given as a mean number of every product variant of each product family 
on all dose levels.  
 
An evident result, as seen in figure 5, is that the number of product variants can be rapidly 
increased by introducing few standardized modules as building blocks for constructing a 
product family. Additionally, the ratio of the number of product variants and the complexity 
factor is showing the same behaviour and thus, this means that the complexity factor, for 
product families embedding modules of several sizes, is not increasing as fast as the number of 
product variants for these families. Thus, a product family consisting of several standardized 
modules would be a suitable design choice for the SODF.  
 
The validity of using the complexity factor as an implication of manufacturing complexity 
needs further investigation, though. In this study, the number of dimensions of a product 
configuration was complicating the usage of the complexity factor. For example, a product 
family could at one dose level consist of several identical product variants regarding the dose 
of the system but different from the size, shape and consequently the release behaviour point of 
view. But, to conduct simple analysis a mean value for each product family was calculated on 
each dose level. The complexity factor seems to be a more suitable approach in the 
manufacturing industry, where the product families are smaller and a complexity factor of each 
configuration can be calculated and analyzed. 
Figure 5. Trade-offs between the sum of the product variants at each dose level, for 5 and 100 dose levels 
and the ratio of the number of product variants and the complexity factor. 
4 Conclusions and future work  
Function-means tree modelling, more specifically the CC method in this study, can be used as 
an approach to modelling a product platform for SODF in ambition to re-design the product 
concept to increase the level of customization. As this was the first attempt at functional 
modelling of SODF only a few vital functions were included in the model. In the future, the 
model should be expanded to include other functional requirements arising from customer 
needs. It should be emphasized that, even though a SODF was used as a means of modelling, 
this model is transferable and generalizable to other concepts of medicinal products beyond the 
SODFs, for example products for parenteral and inhaled administrations including also 
combinations of medical devices and various dosage forms. 
 
Standardized components on a subsystem level provide substantial flexibility on a system level. 
By configuring product variants, from smaller standardized modules, a significant increase in 
the level of customization can be made. Not only can products for a range of different doses be 
provided but as well, by considering assembly sequences, combinations of different sized 
modules and the amount of filling modules, product variants of different sizes and shapes as 
well as products embedding different release behaviour can be generated. However, the 
increasing level of customization has consequences on the manufacturing complexity which 
leads to a conclusion that product design cannot be discussed independently of the 
manufacturing consequences and thus, future studies need to be conducted on expanding the 
model to integrate the production platform as well. Additionally, the model should be expanded 
with some additional cost and value drivers apart from the complexity factor and the number 
of product variants to make a more solid foundation for design decisions. 
 
The validity of using complexity factor as an indication of the assembly cost cannot be 
confirmed and thus, the model needs to be expanded to suit modelling of pharmaceutical 
products better. 
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